Cyril Amarchand Mangaldas advises on CIRP of Sharon Bio-Medicine

August 02, 2023 01:31 AM PDT | By Businesswire India
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Cyril Amarchand Mangaldas advises on CIRP of Sharon Bio-Medicine
Image source: Businesswire India
Business Wire India
Cyril Amarchand Mangaldas acted as legal counsel for Resolution Professional (RP) and Monitoring Committee of Sharon Bio-Medicine Limited in the corporate insolvency resolution process (CIRP) of Sharon Bio-Medicine Limited (Sharon), a listed Indian pharmaceutical company. During the CIRP under the Insolvency and Bankruptcy Code, 2016 (Code), the Resolution Plan (Resolution Plan) submitted by Innova Captab Limited (‘Successful Resolution Applicant’/ ‘Innova’) and approved the Hon’ble National Company Law Tribunal, Mumbai Bench (NCLT) was successfully implemented, resulting in acquisition of 100% shareholding of Sharon through its subsidiary Univentis Medicare Limited.

The Project & Project Finance, Insolvency & Dispute Resolution Practices of Cyril Amarchand Mangaldas (CAM) advised Mr. Pulkit Gupta, Resolution Professional (RP) during the CIRP till the successful approval of the Resolution Plan, including evaluation and compliance check of the resolution plans submitted by the prospective resolution applicants, and negotiation on the resolution plans.

The CAM Team also advised and represented the RP in various litigations before the Hon’ble NCLT, the Hon’ble National Company Law Appellate Tribunal, New Delhi and the Hon’ble Supreme Court.

The Firm also advised the Monitoring Committee (comprising of the erstwhile RP (as Monitoring Agent), the nominee of the Committee of Creditors (CoC) and the Successful Resolution Applicant) constituted for supervision and implementation of the Resolution Plan. The Resolution Plan was successfully implemented on June 30, 2023, culminating into acquisition of 100% shareholding of the Corporate Debtor by the subsidiary of the Resolution Applicant, i.e., Univentis Medicare Limited.

The transaction team was led by Madhav Kanoria, Partner; with support from Surbhi Pareek, Principal Associate; Srideepa Bhattacharyya, Principal Associate; Anush Mathkar, Principal Associate; Jeta Shree, Senior Associate; Neha Shivhare, Senior Associate; Nayani Agarwal, Associate and Jayesh Karnawat, Associate; who advised the Resolution Professional during the entire corporate insolvency resolution process, including invitation, evaluation and final approval of the resolution plan as well as litigation related aspects of the matter. The team also advised the Committee of Creditors and Monitoring Committee on various aspects of resolution process from time to time.

As part of the transaction, the CIRP was initiated for Sharon pursuant to order of the Hon’ble NCLT, Mumbai, dated April 11, 2017. This is one of the few cases under the Code, in which the earlier successful resolution applicant defaulted in implementing its approved resolution plan leading to inordinate delay in completion of the CIRP. Subsequently, after prolonged litigation and upon the directions of the Supreme Court vide order dated February 28, 2022 and the Hon’ble NCLT vide order dated June 3, 2022, fresh CIRP was initiated in relation to the Corporate Debtor. During the re-initiated CIRP, the Resolution Plan of the Innova was approved by the CoC and the Hon’ble NCLT and was successfully implemented on June 30, 2023. The Resolution Plan resolves a total debt aggregating to INR 9,20,31,69,711 of the Corporate Debtor of which the debt owed to the financial creditors was approximately INR 8,91,77,02,779.
 
Other parties and advisors to the transaction included EY Restructuring LLP (acted as advisor for Mr. Pulkit Gupta -Resolution Professional /Sharon Bio-Medicine Limited).
 
The Resolution Plan was approved by the NCLT, Mumbai on 17th May, 2023 and transaction closed on 30th June, 2023.

"Kalkine Media dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum."

Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC

"Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium do Kalkine que laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui do Kalkine Media quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui do Kalkine eum fugiat quo voluptas nulla pariatur?"

1914 translation by H. Rackham

"But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?"

1914 translation by H. Rackham

"But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?"

To keep reading, please log in to your account, create a free account, or simply fill out the form below.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Recent Articles

Investing Tips

Previous Next